



Mr. JONI CHANDRO

PID NO: 46145

Age: 34 Years Sex: Male DOB: 13-Oct-1990

Reference: Dr. AISHA UMER

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Duba

VID: 5080102610

Collected on:

Registered on: 09-Aug-2025 12:15 PM

Reported on :

Abnormal Result(s) Summary

Test Name	Result Value	Unit	Reference Range	
WBC COUNT	11.4	10^3/µL	4 - 11	
EOSINOPHILS	9	%	0 - 6	
ABSOLUTE EOSINOPHIL COUNT	1.03	10^3/uL	0 - 0.66	

Abnormal Result(s) Summary End

This is an Electronically Authenticated Report.

09-Aug-2025 03:02 PM

Printed on:







Mr. JONI CHANDRO

PID NO: 46145

Age: 34 Years Sex: Male DOB: 13-Oct-1990

Reference: Dr. AISHA UMER

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5080102610

Collected on:

08-Aug-2025 02:35 PM

Registered on:

09-Aug-2025 12:15 PM

Reported on:

09-Aug-2025 02:59 PM

<u>Investigation</u>	Observed Value	Flag	<u>Unit</u>	Biological Reference Int	terval <u>Method</u>	
COMPLETE BLOOD COUNT (CBC)						
HEMOGLOBIN	15.7		g/dL	13.5 - 17.5	Photometric	
RBC COUNT	5.5		10^6/μL	4.3 - 5.7	Electrical Impedance	
HEMATOCRIT	46.4		%	38 - 50	Calculation	
MCV	84.0		fL	82 - 98	Calculation	
мсн	28.5		pg	27 - 32	Calculation	
мснс	33.9		g/dL	32 - 37	Calculation	
* RDW	14.0		%	11.8 - 15.6 Calculation		
* RDW-SD	41.10		fL		Calculation	
MPV	9.4		fL	7.6 - 10.8	Calculation	
PLATELET COUNT	280		10^3/uL	150 - 450	Electrical Impedance	
* NUCLEATED RBC (NRBC)	0.0		/100 WBC		VCS 360 Technology	
* ABSOLUTE NRBC COUNT	0		10^3/uL		Calculation	
TOTAL & DIFFERENTIAL COUNT (DC)						
WBC COUNT	11.4	Н	10^3/μL	4 - 11	Electrical Impedance	
NEUTROPHILS	55		%	40 - 75	VCS 360 Technology	
LYMPHOCYTES	31		%	20 - 45	VCS 360 Technology	
EOSINOPHILS	9	Н	%	0 - 6	VCS 360 Technology	
MONOCYTES	5		%	1 - 6	VCS 360 Technology	
BASOPHILS	0		%	0 - 1	VCS 360 Technology	
ABSOLUTE COUNT						
ABSOLUTE NEUTROPHIL COUNT	6.27		10^3/uL	1.6 - 8.25	Calculation	
ABSOLUTE LYMPHOCYTE COUNT	3.53		10^3/uL	0.8 - 4.95	Calculation	
ABSOLUTE MONOCYTE COUNT	0.57		10^3/uL	0.04 - 0.66	Calculation	
ABSOLUTE EOSINOPHIL COUNT	1.03	Н	10^3/uL	0 - 0.66	Calculation	
ABSOLUTE BASOPHIL COUNT	0		10^3/uL	0 - 0.11	Calculation	

Sample Type: EDTA Whole Blood

Cyona V. Shah

DR. ADLEY MARK FERNANDES DR. VYOMA SHAH M.D (Pathology) M.D (Pathology) **Pathologist Clinical Pathologist**

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*). Test marked with # is performed in an accredited referral laboratory.



ANJUMOL VADAKKINATHU

Laboratory Technologist

09-Aug-2025 03:02 PM







Mr. JONI CHANDRO

PID NO: 46145

Age: 34 Years Sex: Male

DOB: 13-Oct-1990

Reference: Dr. AISHA UMER

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5080102610

Tel: 971 4 398 8567 www.biosytech.com

Collected on:

08-Aug-2025 02:35 PM

Registered on:

09-Aug-2025 12:15 PM

Reported on:

09-Aug-2025 01:35 PM

Observed Value Flag Unit **Biological Reference Interval**

* C-REACTIVE PROTEIN (CRP)

(Serum, Particle-enhanced immunoturbidimetric assay)

< 0.6 mg/L < 5.0

Please note change. Source: Roche IFU.

INTERPRETATION:

Investigation

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

----- End Of Report -----

DR. ADLEY MARK FERNANDES

M.D (Pathology) **Pathologist**

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist**

agena V. Shah

This is an Electronically Authenticated Report.

ACCREDITED

192 - LBPMBe 3 of 3



Printed on: 09-Aug-2025 03:02 PM

ELOISA MAY DELMO

Laboratory Technologist

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*). Test marked with # is performed in an accredited referral laboratory.